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Inhibition of IRE1 RNase activity modulates the
tumor cell secretome and enhances response to
chemotherapy
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Triple-negative breast cancer (TNBC) lacks targeted therapies and has a worse prognosis
than other breast cancer subtypes, underscoring an urgent need for new therapeutic targets
and strategies. IRE1 is an endoplasmic reticulum (ER) stress sensor, whose activation is
predominantly linked to the resolution of ER stress and, in the case of severe stress, to cell
death. Here we demonstrate that constitutive IRE1 RNase activity contributes to basal pro-
duction of pro-tumorigenic factors IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2 in TNBC cells. We
further show that the chemotherapeutic drug, paclitaxel, enhances IRE1 RNase activity and
this contributes to paclitaxel-mediated expansion of tumor-initiating cells. In a xenograft
mouse model of TNBC, inhibition of IRE1 RNase activity increases paclitaxel-mediated tumor
suppression and delays tumor relapse post therapy. We therefore conclude that inclusion of
IRE1 RNase inhibition in therapeutic strategies can enhance the effectiveness of current
chemotherapeutics.
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Inositol requiring enzyme 1 alpha (referred to as IRE1 here-after, also known as ERN1), an endoplasmic reticulum (ER)resident type I transmembrane protein, is composed of an N-
terminal ER luminal domain and a C-terminal cytosolic domain
that possesses both kinase and endoribonuclease (RNase) activ-
ities. IRE1 function has been studied extensively during ER stress
where it constitutes an important pro-survival arm of the
unfolded protein response (UPR)1. Accumulation of unfolded
proteins in the ER (ER stress) triggers IRE1 dimerization and
trans-autophosphorylation facilitating its activation2. Activated
IRE1 cleavesX-Box Binding Protein 1 (XBP1) mRNA via its
RNase activity3. Subsequent re-ligation of XBP1 mRNA, by RNA
2′,3′-cyclic phosphate and 5′-OH ligase (RTCB), permits trans-
lation of a transcription factor referred to as spliced XBP1
(XBP1s)4. XBP1s has predominantly been studied within the
context of the UPR where its target genes encode mainly adaptive,
pro-survival factors involved in ER homeostasis5. However,
recent studies indicate that XBP1s has a much broader range of
target genes than previously appreciated. For example, selective
ablation of IRE1/XBP1s signaling in lipopolysaccharide (LPS)-
treated macrophages reduced interleukin (IL)-6 and IL-8 pro-
duction, thus attenuating pro-inﬂammatory responses6. In addi-
tion to XBP1 splicing, IRE1 RNase activity facilitates selective
degradation of RNA by directly cleaving cytosolic RNA species, in
a process referred to as regulated IRE1 dependent decay (RIDD)7.
Similar to the IRE1–XBP1s axis, RIDD signaling has been pre-
dominantly examined in cellular stress responses where it is
associated with both pro-survival and pro-death roles depending
upon the duration and severity of the initiating stress8,9.
The UPR, and in particular, the IRE1–XBP1 branch, has been
linked to tumor development, progression, and post-therapy
responses in a wide range of cancers including breast, prostate,
and pancreatic cancer10–13. The precise mechanism by which
IRE1 RNase signaling promotes cancer progression in these set-
tings is not fully understood. Nevertheless, the IRE1–XBP1s sig-
naling axis has emerged as a potential therapeutic target in cancer
leading to the development of small molecule inhibitors targeting
the IRE1 RNase domain14–17. However, the majority of current
IRE1 RNase inhibitors have poor pharmacodynamic properties
rendering their use as clinical agents unlikely.
In this study, we evaluate the outcome of blocking IRE1 RNase
activity in triple-negative breast cancer (TNBC) cells using a small
molecule inhibitor—MKC8866. MKC8866 is a selective IRE1
RNase inhibitor that exhibits acceptable pharmacokinetic and
toxicity proﬁles, making it an attractive agent for pre-clinical
development. Inhibition of IRE1 RNase activity by MKC8866 in
breast cancer cells leads to the decreased production of pro-
tumorigenic factors including IL-6, IL-8, chemokine (C-X-C)
ligand 1 (CXCL1), transforming growth factor β 2 (TGFβ2), and
granulocyte-macrophage-colony-stimulating-factor (GM-CSF),
linking constitutive IRE1 RNase activity to maintenance of a pro-
tumorigenic secretome.
Chemotherapy-induced modulation of the secretome is a
known promoter of tumor relapse18,19. Paclitaxel, a commonly
used chemotherapeutic for the treatment of TNBC, has been
linked to the production of pro-tumorigenic factors18,19. Our
results demonstrate that this occurs in a manner partly dependent
on IRE1 RNase activity, leading us to propose that the combi-
nation of IRE1 RNase inhibitors with chemotherapeutics, such as
paclitaxel, may be more efﬁcacious than chemotherapy alone.
Indeed, we observe decreased mammosphere formation post-
paclitaxel treatment in MKC8866-treated TNBC cells compared
to those treated with vehicle alone. Likewise, in vivo, MKC8866
administered in combination with paclitaxel enhances the effec-
tiveness of paclitaxel and limits tumor regrowth upon cessation of
paclitaxel treatment.
Results
Breast cancer cells exhibit constitutive IRE1 RNase activity. A
panel of breast cancer cell lines encompassing the main molecular
subtypes (estrogen receptor positive—MCF7, T47D, Human
Epidermal growth factor Receptor 2 (HER2) positive—SKBR3
and triple negative—MDA-MB-231, MDA-MB-468) was exam-
ined for basal IRE1 RNase activity by assessing levels of spliced
XBP1. In all breast cancer lines tested, XBP1s mRNA was
detected, to varying degrees, with the highest levels present in
TNBC cells (Fig. 1a). Examination of XBP1s protein expression
revealed a similar pattern with the highest expression evident in
the TNBC cell lines MDA-MB-231 and MDA-MB-468 (Fig. 1b).
MCF10A, a spontaneously immortalized, non-transformed, non-
tumorigenic breast epithelial cell line, did not display basal IRE1
RNase activity (Fig. 1a, b). However, treatment of MCF10A cells
with the ER stress inducer, Tunicamycin (Tm), triggered sig-
niﬁcant XBP1 splicing, indicating that IRE1 RNase, while not
constitutively active, is functional in these cells (Fig. 1a, b). In
addition to commonly used breast cancer cell lines IRE1 RNase
activity was also assessed by quantitative PCR (Q-PCR) in a range
of primary patient samples. Similar to the results obtained in the
breast cancer cell lines, the ratio of spliced to total XBP1 was
highest in samples derived from basal-like breast cancers (most of
which are TNBC) compared to luminal samples, and tumor-
associated normal tissue (TAN) (Fig. 1c).
Inhibition of IRE1 reduces breast cancer cell proliferation.
MKC8866 (Fig. 2a) is a member of a small molecule IRE1 RNase
inhibitor family ﬁrst described by Patterson and colleagues in
201114. It is a salicylaldehyde analog, that binds to IRE1 within
the RNase catalytic site and inhibits both XBP1 splicing and
RIDD activity14. Addition of MKC8866 rapidly attenuated basal
IRE1 RNase activity in MDA-MB-231 cells, as demonstrated by
decreased levels of XBP1s transcript and its downstream targets
endoplasmic reticulum DNA J domain-containing protein 4
(ERDJ4, also known as DNAJB9) and homocysteine-responsive
ER protein with ubiquitin like domain 1 (HERP, also known as
HERPUD1) (Fig. 2b). Addition of MKC8866 blocked Tm-induced
IRE1-mediated signaling but did not affect Tm-induced
activation of the other two arms of the UPR, protein kinase R
(PKR)-like endoplasmic reticulum kinase (PERK) or activating
transcription factor 6 (ATF6) (Fig. 2c). Indeed, neither PERK
phosphorylation and downstream CHOP induction, nor ATF6
processing were affected by MKC8866, underscoring the selec-
tivity of MKC8866 for IRE1 under both basal and stress condi-
tions. To examine the effect of the constitutive IRE1 signaling
observed in breast cancer cells, IRE1 RNase activity was blocked
by addition of MKC8866 and the outcome on cell proliferation/
viability was assessed (Fig. 2d, e, Supplementary Fig. 1a, b).
Addition of MKC8866 decreased proliferation of all breast cancer
cell lines tested without inducing cell death (Fig. 2d, Supple-
mentary Fig. 1a). Cell cycle analysis, using 5-ethynyl-2′-deox-
yuridine (EdU) incorporation, indicated that inhibition of IRE1
RNase activity by MKC8866 reduced the number of cells entering
S phase (Supplementary Fig. 1b). In contrast, addition of
MKC8866 to MCF10A cells, which do not display constitutive
IRE1 RNase activity, did not alter cell proliferation (Fig. 2d,
Supplementary Fig. 1c). Knockdown of XBP1 or IRE1 in MDA-
MB-231 cells similarly reduced cell proliferation when compared
to controls (Fig. 2f, g, Supplementary Fig. 1d-g).
IRE1 gene signature associates with basal-like breast cancer.
Transcriptomic data obtained from MKC8866 versus vehicle-only
microarray experiments identiﬁed 401 differentially expressed
probe-sets representing 395 genes. These initial candidate
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markers were tested in a training dataset containing gene
expression proﬁles of a panel of 27 breast cancer cell lines. Genes
with a strong positive or negative correlation with IRE1 activity
were further prioritized using BioInfoMiner to generate an 83-
gene signature predictive of IRE1 activity (IRE1 gene signature)
(Supplementary Table 1). This IRE1 gene signature was applied to
the 27 breast cancer cell lines, ranking them based on their pre-
dicted level of IRE1 RNase activity (Fig. 3a). The resultant
ranking largely mirrored results achieved by western blotting for
XBP1s (Fig. 1b) with those cell lines representative of TNBC
being ranked highest (MDA-MB-231) while those lines repre-
sentative of HER2-positive (SKBR3) and estrogen receptor-
positive (T47D) ranked lower. We then applied the IRE1 gene
signature to a cohort of 595 breast cancer tumors from The
Cancer Genome Atlas (TCGA) database and, using the same
approach, identiﬁed two distinct subsets of patients indicative of
low (n= 79) and high IRE1 (n= 63) activity (Fig. 3b). Analysis of
the breast cancer subtype in each, based on PAM50 classiﬁcation
criteria20, revealed that a high IRE1 gene signature associated
exclusively with basal-like breast cancers, while tumors associated
with a low IRE1 gene signature were predominantly of the
luminal subtype (Fig. 3c). Gene set enrichment analysis (GSEA)
indicated cancers with an elevated IRE1 gene signature associated
with a more mesenchymal-like phenotype, increased invasiveness
and a worse clinical outcome (Supplementary Fig. 2).
IRE1 activity induces production of pro-inﬂammatory factors.
To identify biological processes associated with constitutive IRE1
RNase activity in breast cancer patients, we again applied the
IRE1 gene signature to the 595 breast cancer tumors from TCGA
database. An IRE activity score for each tumor was predicted
based on expression levels of the 83 genes from the IRE1 gene
signature and the Pearson correlation coefﬁcient was calculated
between the score and every other gene across 595 tumors to
produce a ranked gene list. We then performed GSEA using gene
ontology terms on the ranked gene list. Using this approach, we
found that predicted IRE1 activity strongly associates with the
expression of genes involved in inﬂammatory responses (Sup-
plementary Fig. 3). We also noted that genes encoding pro-
inﬂammatory factors (IL6, IL8, and TGFB2) comprised a subset
of the downregulated genes in the microarray experiment, sug-
gesting a link between IRE1 RNase activity and the production of
pro-inﬂammatory factors in TNBC cells.
Comparison of IL6, IL8, GM-CSF, CXCL1, and TGFB2 mRNA
expression levels between the IRE1 RNase high and IRE1 RNase
low activity populations within the 595 patient cohort from
TCGA revealed a signiﬁcantly higher expression level of each pro-
inﬂammatory factor in the IRE1 RNase high grouping (Fig. 3d).
Examination of pro-tumorigenic cytokine and XBP1s expression,
via immunohistochemistry, showed that high XBP1s expression
positively correlates with elevated IL-8 and CXCL1 staining in
human TNBC tissue sections (Fig. 3e, f) supporting our in silico
ﬁndings.
To further investigate this link we generated conditioned
medium from MDA-MB-231 cells following 48 h treatment with
MKC8866 or vehicle alone. Once equal cell number post
treatment was conﬁrmed (Supplementary Fig. 4a), the condi-
tioned medium was applied to a cytokine array assaying 102
different factors. Using this approach we observed reduced levels
of IL-6, IL-8, GM-CSF, and CXCL1 in MKC8866 conditioned
medium compared to vehicle-only conditioned medium (TGFβ2
was not present on the array) (Fig. 4a). Using a combination of
ELISAs and Q-PCR, we conﬁrmed that inhibition of IRE1 RNase
activity by MKC8866 treatment reduced the production and
secretion of IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2 in MDA-
MB-231 cells (Fig. 4b–d). We also tested the effect of MKC8866
addition on IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2 secretion in
three additional TNBC cell lines (MDA-MB-468, BT-549, and
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Fig. 1 Breast cancer cells exhibit constitutive IRE1 RNase activity. a Expression of spliced and unspliced XBP1 mRNA was assessed in a panel of breast
cancer cell lines (MCF7, SKBR3, MDA-MB-231) and the non-tumorigenic breast epithelial cell line MCF10A via RT-PCR. Tunicamycin (Tm) (1 μgml−1)-
treated MCF10A cells act as a positive control for XBP1 splicing. GAPDH was used as a loading control. b Immunoblotting of XBP1s in a panel of breast
cancer cell lines (MCF7, T47D, SKBR3, MDA-MB-231, and MDA-MB-468) and the non-tumorigenic breast epithelial cell line MCF10A. Tm (1 μg ml−1)-
treated MCF10A cells act as a positive control for XBP1 splicing. Actin was used as a loading control. c Q-PCR quantiﬁcation of the relative mRNA levels of
spliced to total XBP1 in RNA samples obtained from basal-like tumor tissue (n= 5), luminal tumor tissue (n= 4), and tumor-associated normal (TAN)
tissue (n= 4). Results shown for a and b are representative of three independent experiments. *P < 0.05 based on a pairwise single factor ANOVA tests
comparing each tissue type. Error bars represent s.e.m.
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HCC1806). However, CXCL1 was the only common factor
signiﬁcantly reduced by MKC8866 (Fig. 4e) in all cell lines tested,
suggesting IRE1 RNase activity may be of particular importance
in regulating CXCL1 production in TNBC cells.
To validate that the effect of MKC8866 on cytokine production
was indeed a consequence of reduced IRE1 RNase signaling we
knocked down IRE1 expression in MDA-MB-231 cells by siRNA
and examined secretion of IL-6, IL-8, TGFβ2, GM-CSF, and
CXCL1. With the exception of TGFβ2, IRE1 knockdown reduced
the secretion of each cytokine to levels observed in non-targeting
siRNA controls (NC) treated with MKC8866 (Supplementary
Fig. 4b-d). In agreement with these data, analysis of transcript
levels demonstrated a similar pattern with a reduction in all
factors, again with the exception of TGFβ2, observed in IRE1
knockdown cells compared to NC (Supplementary Fig. 4e).
Likewise, knockdown of XBP1 reduced transcript levels of IL6,
IL8, GM-CSF, CXCL1, and to a lesser extent TGFB2
(Supplementary Fig. 4e). Since TGFβ2 regulation upon IRE1
knockdown differed to the results obtained with MKC8866, we
questioned whether this was an off-target effect of MKC8866. To
examine this, we added MKC8866 to both NC and IRE1
knockdown cells. While MKC8866 suppressed TGFβ2 secretion
in NC controls it failed to do so in IRE1 knockdown cells
verifying its reliance on IRE1 expression (Supplementary Fig. 4d).
It is possible that reducing protein expression of IRE1 triggers a
compensatory increase in TGFβ2 production through IRE1-
independent mechanisms.
Collectively, these ﬁndings indicate that constitutive IRE1
RNase activity in MDA-MB-231 cells contributes to the
composition of the secretome and that addition of a small
molecule IRE1 RNase inhibitor, MKC8866, can limit the
production of secreted pro-tumorigenic factors. Since MKC8866
addition slowed the proliferation rate of MDA-MB-231 cells we
asked whether any of the cytokines identiﬁed as being regulated
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in an IRE1 RNase-dependent manner contributed to cell
proliferation. To this end, we incubated MDA-MB-231 cells with
either MKC8866 or neutralizing antibodies against each of
CXCL1, IL-6, IL-8, GM-CSF, and TGFβ2. We observed a
decrease in MDA-MB-231 cell proliferation, comparable to that
observed with MKC8866, following administration of anti-
CXCL1, IL-6, IL-8, GM-CSF, and TGFβ2 antibodies (Supple-
mentary Fig. 4f).
Paclitaxel increases IRE1-dependent cytokine secretion. Neo-
adjuvant chemotherapy is the current standard of care for TNBC
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patients. To determine if chemotherapeutics such as paclitaxel
impact IRE1 RNase activity, MDA-MB-231 cells were treated
with therapeutically relevant concentrations of paclitaxel and
IRE1 RNase activity was assessed. Paclitaxel concentrations as low
as 10 nM increased IRE1 RNase activity as demonstrated by an
increase in levels of XBP1s protein (Fig. 5a). Moreover, addition
of MKC8866 was sufﬁcient to completely block paclitaxel-
induced expression of XBP1s (Fig. 5b). Since our results
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Fig. 4 IRE1 activity induces production of pro-inﬂammatory factors. a–dMDA-MB-231 cells cultured in medium containing 2% serum were treated with 20
μM MKC8866 or vehicle alone for 48 h after which cells and conditioned medium were collected. a Conditioned medium was applied to a Human XL
Cytokine Array. Expression proﬁle of cytokines in vehicle alone versus MKC8866-conditioned medium was determined by chemiluminescence. b, c
Cytokine secretion was quantiﬁed in conditioned medium using ELISAs selective for IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2 (n= 3). d mRNA transcript
levels of IL6, IL8, CXCL1, GM-CSF, TGFB2, and XBP1s were quantiﬁed by Q-PCR (n= 3). e CXCL1 quantiﬁcation in conditioned medium collected from
HCC1806, BT549, and MDA-MB-468 cells treated for 48 h in 2% serum-containing medium supplemented with vehicle alone or 20 μM MKC8866 (n=
3). Results shown for a are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001, based on a Student’s t
test. Error bars represent s.e.m.
Fig. 3 IRE1 gene signature associates with basal-like breast cancers. a The putative IRE1 RNase-dependent gene signature was applied to a gene expression
data set comprised of 27 breast cancer cell lines. Hierarchical clustering was performed and cell lines ranked based on their predicted IRE1 RNase activity.
Expression across each gene (row) was centered and scaled so that mean expression is zero and standard deviation is one. Red indicates those genes with
high expression and blue those with low expression relative to the mean. b IRE1 RNase-dependent gene signature was used to stratify 595 breast cancer
gene expression data sets in TGCA. Cohorts with high and low IRE1 activity where identiﬁed and are represented as a heat map. Red indicates genes with
high expression while blue those with low expression relative to the mean. c Pie charts depicting the breast cancer molecular sub-types (based on PAM50
classiﬁcation) of IRE1 high and IRE1 low cohorts. NA indicates samples where PAM50 classiﬁcation information was not available. d mRNA expression
levels of IL6, IL8, CXCL1, GM-CSF, and TGFB2 in IRE1 high versus IRE1 low cohorts. Box plots show the median, 25th and 75th percentiles, and whiskers
indicate the location of the minimum and maximum values for each of the IRE1 low (n= 79) and IRE1 high (n= 63) groups. e Correlation between
immunohistochemistry staining intensity for XBP1s and IL-8 in TNBC human tumor sections (n= 16). f Correlation between immunohistochemistry
staining intensity for XBP1s and CXCL1 in human TNBC tumor sections (n= 14). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, based on
comparison of the two groups using a two-tailed t test with Welch’s correction. Error bars represent s.e.m.
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indicated that IRE1 RNase activity exerted control over the
secretome and that paclitaxel treatment enhanced IRE1 RNase
activity, we investigated whether paclitaxel treatment could
increase cytokine production in an IRE1 RNase-dependent
manner. We treated MDA-MB-231 cells with vehicle, paclitaxel
or a combination of paclitaxel and MKC8866. Following 72 h
treatment, cells and conditioned medium were harvested and
analyzed for cytokine production. As predicted, we observed a
paclitaxel-induced increase in the secretion of IL-6, IL-8, CXCL1,
and GM-CSF (Fig. 5c). Co-treatment with MKC8866 reduced
paclitaxel-induced increases in CXCL1, GM-CSF, IL-6, and to a
lesser extent IL-8 secretion (Fig. 5c).
Studies have shown that chemotherapy, while effective in the
short term, can lead to tumor relapse in the longer term, with
increases in pro-tumorigenic secreted factors considered key
elements in this process18,19. To assess the longer term impact of
paclitaxel on MDA-MB-231 cells we treated cells with a low dose
(10 nM) of paclitaxel for 72 h, after which paclitaxel was removed,
cells washed and left to recover in fresh medium containing
vehicle alone or MKC8866. After 72 h of recovery, conditioned
medium was collected and cytokine levels were assessed. Addition
of MKC8866 post-paclitaxel treatment signiﬁcantly reduced
CXCL1 and IL-8 levels compared to vehicle-only controls
(Fig. 6a). Since chemotherapy-induced increases in pro-
tumorigenic cytokines have been linked to expansion of tumor-
initiating cell populations, we assessed the ability of paclitaxel-
treated cells incubated with either MKC8866 or vehicle alone
during the recovery phase to form mammospheres (a functional
readout of tumor-initiating cell expansion). Following 72 h of
recovery, cells were counted, equal numbers seeded out onto low-
adherence plates, and 5 days later, mammospheres greater than
40 μm were counted and mammosphere-forming efﬁciency was
calculated. As previously reported18, treatment with paclitaxel
signiﬁcantly increased the mammosphere-forming efﬁciency of
MDA-MB-231 cells (Fig. 6b). Addition of MKC8866 post-
paclitaxel treatment substantially reduced mammosphere forma-
tion when compared to vehicle-only treated controls, suggesting
an important role for IRE1 RNase signaling in this process
(Fig. 6b). Since we had observed a reduction in the levels of
CXCL1 and IL-8 in conditioned medium post-paclitaxel
treatment (Fig. 6a), we asked if these cytokines contributed to
paclitaxel-induced mammosphere formation in MDA-MB-231
cells. To answer this, we depleted CXCL1 and IL-8 levels through
addition of neutralizing antibodies during the 72 h recovery phase
post-paclitaxel treatment and assessed the ability of cells to form
mammospheres. Addition of neutralizing antibodies against
either IL-8 or CXCL1 blocked the ability of paclitaxel-treated
MDA-MB-231 cells to form mammospheres (Fig. 6c, Supple-
mentary Fig. 4g-i). In addition to neutralizing CXCL1 and IL-8,
we carried out a reciprocal experiment where we assessed the
ability of exogenous CXCL1 and IL-8 to overcome MKC8866-
mediated suppression of mammosphere formation. Combination
of MKC8866 with recombinant CXCL1 or IL-8 during the 72 h
recovery phase partially reversed MKC8866-mediated inhibition
of mammosphere formation (Fig. 6d) further underscoring the
importance of these pro-tumorigenic cytokines.
MKC8866 enhances the effectiveness of paclitaxel in vivo. To
determine the efﬁcacy of MKC8866 treatment in vivo, MDA-MB-
231 tumor xenografts were established in athymic nude mice.
Once tumors had reached a palpable size (225–250 mm3), ani-
mals were randomized into treatment groups and treated with
vehicle alone, 300 mg kg−1 MKC8866 alone, 10 mg kg−1 pacli-
taxel alone or a combination of paclitaxel and MKC8866.
Treatments in all groups were administered until tumors reached
maximal size (2000 mm3) or on day 60, whichever came ﬁrst.
MKC8866 was well tolerated after 60 consecutive oral doses and,
based on pharmacokinetic allometric scaling, systemic exposures
were well above anticipated clinical therapeutic levels. Treatment
with MKC8866 alone did not attenuate tumor growth compared
to vehicle-only controls (Fig. 7a). Analysis of percentage XBP1
mRNA splicing in those tumors treated with MKC8866 con-
ﬁrmed a reduction in IRE1 RNase activity verifying on-target
effect (Fig. 7b). While paclitaxel treatment reduced tumor growth,
combination with MKC8866 markedly enhanced the efﬁcacy of
paclitaxel. Signiﬁcantly reduced tumor growth (P ≤ 0.0001) was
observed throughout the 60-day experiment in animals receiving
a paclitaxel-MKC8866 combination compared to paclitaxel alone
(Fig. 7c). A similar synergistic effect was observed following a
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paclitaxel-MKC8866 combination starting on day 14 (or ~700
mm3 tumor volume) (P ≤ 0.001) or on day 28 (or ~1300 mm3
tumor volume) (P ≤ 0.05) when compared to paclitaxel alone
(Fig. 7c). Examination of XBP1 splicing in tumors revealed
paclitaxel treatment increased IRE1 RNase activity, which was
reduced upon combination with MKC8866 (Fig. 7d, Supple-
mentary Fig. 5). The decrease in tumor volume observed fol-
lowing a combination of paclitaxel and MKC8866 also translated
to an increase in survival. Mice receiving daily MKC8866
administration in combination with paclitaxel from day 1 to 60,
day 14 to 60, and day 28 to 60 displayed signiﬁcantly longer
survival compared to those treated with paclitaxel alone (Fig. 7e).
Since our in vitro studies indicated that IRE1 RNase inhibition
by MKC8866 reduced mammosphere formation post-paclitaxel
treatment, we tested the outcome of maintaining IRE1 inhibition
following paclitaxel withdrawal in vivo. Following MDA-MB-231
tumor formation, mice were treated with paclitaxel alone (7.5 mg
kg−1) for days 1–10, or a combination of paclitaxel (days 1–10)
and MKC8866 (300 mg kg−1, days 1–28). After withdrawal of
paclitaxel treatment on day 10, an initial reduction in tumor
volume was apparent in both treatment groups (Fig. 8). Tumor
regrowth, evident after day 18 in those animals receiving no
further treatment, was repressed in the treatment group still
receiving MKC8866. Tumor regrowth was only apparent in this
group following cessation of MKC8866 on day 28 (Fig. 8).
After 28 days of dosing the mice, the maximum systemic
concentration of MKC8866 was ~110 μg ml−1 as measured by
LC/MS/MS with no signs of overt toxicity or signiﬁcant changes
in body weight. Tumor volume measurements revealed 8 out of
10 animals displayed partial tumor regression and 1 animal
showed complete tumor regression in the paclitaxel-MKC8866
combination group (Supplementary Table 2). This compared
favorably to paclitaxel alone, which had just three partial
regressions, one complete regression, and one tumor-free survival
observed (Supplementary Table 2). Additional studies are
required to fully evaluate tumor growth after treatment is
discontinued.
Discussion
The current dogma regarding IRE1 signaling in cancer is very
much aligned with its role as a mediator of the UPR facilitating
cell survival under stress conditions. While this is undoubtedly
an important function of IRE1 signaling especially early in
tumorigenesis21, numerous other reports have linked
IRE1 signaling to facets of tumor biology more aligned with
tumor progression, including angiogenesis and metastasis10,22.
In our system, we identiﬁed IRE1 RNase signaling as an
important modulator of the secretome in TNBC cells. Through
a combination of transcriptomics, Q-PCR, cytokine arrays, and
ELISAs we identiﬁed IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2
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Fig. 7MKC8866 enhances the effectiveness of paclitaxel in vivo. Xenografts were established by subcutaneously injecting 5 × 106 MDA-MB-231 cells into
the right ﬂank of female athymic nude mice (Crl:NU(Ncr)-Foxn1nu, Charles River). When tumors were palpable (250mm3) mice were randomized into
groups and treatments initiated. a Vehicle-only versus MKC8866 (300mg kg−1) daily via oral gavage. Tumor size was assessed every 2–3 days via caliper
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as factors regulated in an IRE1-dependent manner in MDA-
MB-231 cells. Previous reports have linked IRE1-dependent
signaling, via direct XBP1s transcriptional upregulation, to both
IL-6 and IL-8 production in innate immune cells and most
recently in melanocytes23–25 but a role for IRE1 RNase activity
in promoting CXCL1, GM-CSF, or TGFβ2 expression has not
been previously reported. Cells transfected with XBP1 siRNA
displayed decreased transcript levels of all cytokines
tested suggesting a direct IRE1–XBP1s signaling mechanism.
However, given that XBP1 knockdown also reduced IRE1
transcript levels, further studies are required to determine the
exact mechanism. Examination of nuclear-factor-kappa-light-
chain-enhancer of activated B cells (NF-κB), signal transducer
and activator of transcription 3 (STAT3), and hypoxia-
inducible-factor-1α (HIF1α) in MDA-MB-231 cells following
MKC8866 treatment did not detect any change in the activation
of these transcription factors in MDA-MB-231 cells (Supple-
mentary Fig. 6). Irrespective of the precise signaling
pathway our work clearly demonstrates a link between IRE1
RNase activity and the production of soluble factors by TNBC
cells.
IL-6, IL-8, CXCL1, GM-CSF, and TGFβ2 are recognized pro-
tumorigenic factors associated with cancer progression18,26–28.
Elevated serum and tissue levels of IL-6 and IL-8 are markers of
poor clinical outcome in breast cancer29–32 and, along with
CXCL1, both IL-6 and IL-8 have been implicated in TNBC tumor
progression in vivo26,28. The tumor secretome has been linked to
the recruitment of diverse cell types establishing a pro-
tumorigenic microenvironment. CXCL1 and GM-CSF have
been reported to recruit myeloid-derived suppressor cells
(MDSCs), a cell type connected to tumor angiogenesis and T cell
immunosuppression28,33 while IL-8 and IL-6 have been linked to
the recruitment of mesenchymal stem cells and neutrophils
amongst others. This suggests that inhibiting IRE1 RNase activity
could be an effective way of limiting the impact of the tumor cell
secretome on both the tumor itself and the wider tumor micro-
environment. Indeed, recent work in glioblastoma multiform
supports this viewpoint. Lhomond and colleagues linked
enhanced IRE1–XBP1s signaling to the promotion of angiogen-
esis, invasion, and macrophage recruitment34.
While undoubtedly important in cancer progression, the
impact of the tumor secretome is particularly pertinent post
therapy. Currently, neo-adjuvant chemotherapy is the only
treatment option available to TNBC patients. Although successful
in the short term, a large number of patients relapse within 1–3
years35 with cancer stem cell expansion, a key determinant in
tumor relapse36,37. This subset of tumor cells, which are highly
resistant to chemotherapy and radiation, drive tumor re-
establishment resulting in drug resistant, rapidly proliferating
and highly metastatic tumors refractory to treatment. Therapy-
induced changes in the tumor secretome have been identiﬁed as a
driver of cancer stem cell expansion. In breast cancer speciﬁcally,
cancer stem cell expansion post therapy has been reported37,38
and shown to be dependent on the production of several pro-
tumorigenic factors including IL-6, IL-8, and TGFβ18,19,39. As
such, developing therapies to reduce cancer stem cell expansion is
key to limiting tumor re-emergence post therapy. Several studies
have already illustrated the potential of targeting pro-tumorigenic
factors post therapy in breast cancer. Inhibitors of C–X–C motif
chemokine receptor 1 (CXCR1), the IL-8 receptor, and antag-
onistic TGFβ antibodies have been demonstrated to reduce can-
cer stem cell expansion and limit tumor relapse post therapy18,39.
Similar to published ﬁndings, we observed increased cytokine
production post-paclitaxel treatment in MDA-MB-231 cells. Our
study takes this further, demonstrating a link between increased
pro-tumorigenic cytokine production and a therapy-induced
increase in IRE1 RNase activity. Combining MKC8866 with
paclitaxel inhibited splicing of XBP1 and reduced production of
pro-tumorigenic cytokines in vitro. Mammosphere formation, a
widely used functional readout for tumor-initiating cells, was
signiﬁcantly increased in MDA-MB-231 cells following paclitaxel
treatment. Addition of MKC8866, post-paclitaxel treatment,
reduced mammosphere formation indicating a requirement for
IRE1 RNase activity. Analysis of conditioned medium revealed
MKC8866 addition reduced the levels of both CXCL1 and IL-8.
Moreover, addition of neutralizing antibodies against IL-8 or
CXCL1 post paclitaxel also reduced mammosphere formation.
These data suggest reduced mammosphere formation in
MKC8866-paclitaxel-treated cells is a likely consequence of
decreased cytokine production. Similar to our ﬁndings, Chen and
colleagues, using an inducible shRNA-mediated knockdown of
XBP1, recently linked XBP1 expression to cancer stem cell
expansion and tumor relapse post therapy, although a role for the
secretome in this process was not extensively explored10. While
genetic knockdown is a powerful experimental tool, it is not a
viable therapeutic strategy easily translatable to patients unlike a
small molecule inhibitor. In vivo, we found daily MKC8866
administration to be well tolerated in mice with no toxicity evi-
dent after 60 consecutive daily oral doses at 300 mg kg−1.
Although not effective as a single agent in the TNBC xenograft
model, MKC8866 signiﬁcantly enhanced paclitaxel-mediated
repression of tumor growth. Additionally, maintenance of IRE1
RNase inhibition post-paclitaxel withdrawal sustained suppres-
sion of tumor regrowth, conﬁrming in vivo, that blocking IRE1
RNase may increase the efﬁcacy of chemotherapeutic agents such
as paclitaxel.
Our study supports IRE1 as a therapeutic target in TNBC and
illustrates the therapeutic potential of small molecule IRE1 RNase
inhibitors in TNBC treatment. Recently published ﬁndings by
Zhao and colleagues further support this view, demonstrating
pharmacological inhibition of the IRE1–XBP1 pathway
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Fig. 8 MKC8866 reduces tumor regrowth post-paclitaxel withdrawal.
Xenografts were established by subcutaneously injecting 5 × 106 MDA-MB-
231 cells into the right ﬂank of female athymic nude mice (Crl:NU(Ncr)-
Foxn1nu, Charles River). When tumors were palpable (250mm3) mice were
randomized into groups and treatments initiated. Paclitaxel (7.5 mg kg−1 by
intravenous injection) was administered every second day until day 10 (last
dose indicated by the black arrow) as a single agent or in combination with
MKC8866 (300mg kg−1 by oral gavage). MKC8866 treatment was
administered daily from day 1 to 28 (last dose indicated by the red arrow).
Tumor size was assessed every 2–3 days via caliper measurement and
tumor volume calculated (n= 10 mice per group). *P < 0.05, **P < 0.01
based on a Student’s t test. Error bars represent s.e.m.
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suppresses MYC-driven breast cancers40. To extrapolate our
in vitro ﬁndings to primary patient-derived samples, we gener-
ated a putative IRE1 gene signature reﬂective of IRE1 RNase
activity. When applied to TCGA breast cancer gene expression
data sets, this gene signature identiﬁed two distinct cohorts
reﬂective of IRE1 RNase high and IRE1 RNase low activities.
Examination of these groupings revealed that breast cancers
characterized by a high IRE1 gene signature associated with basal-
like breast cancers and exhibited increased expression of pro-
inﬂammatory factors when compared to those with low IRE1
gene signature. These data, in conjunction with our in vitro cell
line ﬁndings, strongly support the hypothesis that an elevated
IRE1 RNase activity is associated with basal-like/TNBC. The
development of genetic signatures such as this could enable the
identiﬁcation of breast cancer patients most likely to beneﬁt from
treatment with IRE1 RNase inhibitors and act as a companion
diagnostic. In conclusion, our work demonstrates a role for
IRE1 signaling as an important regulator of the TNBC cell
secretome and provides compelling evidence to support the use of
IRE1 RNase inhibitors in combination with chemotherapeutics
for the treatment of TNBC.
Methods
Cell culture and treatments. MCF10A (ATCC) cells were maintained in DMEM/
F-12 (Gibco, 11320-074) supplemented with 5% horse serum (Sigma-Aldrich,
H1270), 20 ng ml−1 epidermal growth factor (PeproTech, AF-100-15), 0.5 μg ml−1
Hydrocortisone (Sigma-Aldrich, H0888), 100 ng ml−1 Cholera toxin (Sigma-
Aldrich, C8052), 10 μg ml−1 insulin (Sigma-Aldrich, I1882), 50 Uml−1 penicillin,
and 50 μg ml−1 streptomycin (Sigma-Aldrich, P0781). MCF7 cells (ECACC) were
cultured in DMEM high glucose (Sigma-Aldrich, D6429), SKBR3 (ECACC) cells in
McCoys5A (Sigma-Aldrich, M9309), HCC1806 cells (ATCC), and BT549 (ATCC)
in RPMI-1640 medium (Sigma-Aldrich, R0883) supplemented with 10% fetal
bovine serum (FBS) (Sigma-Aldrich, F7524), 50 Uml−1 penicillin, 50 μg ml−1
streptomycin (Sigma-Aldrich, P0781), and 2 mM L-glutamine (Sigma-Aldrich,
G7513). MDA-MB-231 cells obtained from ATCC and ECACC were used in this
study. MDA-MB-231 cells were cultured in DMEM high glucose (Sigma-Aldrich,
D6429) supplemented with 10% FBS, 50 Uml−1 penicillin, 50 μg ml−1 strepto-
mycin, and 2 mM L-glutamine. The data from both cell clones were similar. Cells
from ATCC were tested and were mycoplasma negative. HEK293T cells were from
ATCC and were cultured in DMEM high glucose supplemented with 10% FBS, 2
mM L-glutamine, 50 Uml−1 penicillin, and 50 μg ml−1 streptomycin. All cells were
cultured at 37 °C, 5% CO2 in a humidiﬁed incubator and seeded at an appropriate
number 24 h prior to treatment. Cells were treated with the indicated concentra-
tions of MKC8866 (Fosun Orinove PharmaTech Inc.), Tunicamycin (Tm) (Sigma-
Aldrich, T7765), Thapsigargin (Tg) (Sigma-Aldrich, T9033), Paclitaxel (Sigma-
Aldrich, T7402), Boc-D-fmk (Biovision, 1160-5), Etoposide (Sigma-Aldrich,
E1383), or an equal volume of DMSO (Sigma-Aldrich, D2650). Neutralizing
antibodies against IL-6 (R&D Systems, MAB206), IL-8 (R&D Systems, MAB208),
CXCL1 (R&D Systems, MAB275), and GM-CSF (R&D Systems, MAB215) were
used at 0.5 μg ml−1, while TGFβ2 neutralizing antibody (R&D Systems, AF302)
was used at 1.12 μg ml−1.
Western blotting. Cells were washed once in ice-cold phosphate-buffered saline
(PBS) and lysed in whole cell lysis buffer (2% sodium dodecyl sulfate (SDS), 50 mM
Tris HCl pH 6.8, 5% glycerol, 0.05% bromphenol blue, 357 mM β-mercaptoetha-
nol) or radioimmunoprecipitation assay (RIPA) buffer (0.1% SDS, 1% NP-40, 0.5%
sodium deoxycholate, 50 mM Tris-HCl pH 8.8, 150 mM NaCl) after indicated
treatments and cell lysate boiled at 95 °C for 5 min. Protein samples were separated
on an SDS polyacrylamide gel, transferred onto nitrocellulose membrane (Amer-
sham Protran 0.2 10600001) and blocked with 5% milk in PBS-0.1% Tween. For
detection of protein expression the following antibodies were used: Actin (Sigma-
Aldrich, A-5060, 1:5000), XBP1 (Abcam, 37152, 1:1000), XBP1s (Biolegend,
647502, 1:1000), PERK (CST, 3192, 1:1000), CHOP (CST, 2895, 1:1000), ATF6
(CosmoBio, AM-73-500-B, 1:1000), phospho-p65 (CST 3033, 1:1000), total-p65
(CST 8242, 1:5000), phospho-STAT3 (SantaCruz, 8059, 1:1000), total-STAT3
(Santa Cruz, 482, 1:1000), β-catenin (CST 8480, 1:1000), FOXO1 (CST 2880,
1:1000), and HIF1α (Novus Biologicals, NB100-479, 1:1000). Anti-rabbit (111-035-
003) and anti-mouse (115-035-003) HRP-conjugated secondary antibodies were
purchased from Jackson Immunoresearch and the signal was visualized using
western blotting luminol reagent (SantaCruz, sc-2048). Uncropped western blot
images are shown in Supplementary Fig. 7.
EdU incorporation assay. S phase cells were determined using EdU (Berry &
Associates PY7563) according to manufacturer’s instructions. Post-treatment cells
were trypsinised, washed with PBS, and ﬁxed in 70% ice-cold ethanol for 1 h before
storing at −20 °C. After thawing cells were washed in PBS, resuspended in 1 ml of
Click cocktail (10 mM sodium ascorbate, 100 μM 5′ ﬂuorescein isothiocyanate
azide and 2 mM copper II sulfate) and incubated in the dark at room temperature
for 30 min. The signal was quenched by adding 10 ml PBS, 0.5% Tween-20, and 1%
bovine serum albumin (BSA) for 10 min at room temperature. Samples were then
washed with PBS and analyzed on the FL1 channel of a FACSCalibur ﬂow cyt-
ometer (Becton Dickinson).
Propidium iodide assessment of cell death. Membrane permeability was
assessed using propidium iodide (PI) staining. Brieﬂy, cells were harvested by
trypsinization and incubated 15 min at 37 °C to restore membrane integrity. Cells
were collected by centrifugation, resuspended in PBS, stained with 0.6 μg ml−1 of
PI (Sigma-Aldrich 81845), and analyzed using a FACSCalibur ﬂow cytometer
(Becton Dickinson).
Generation of conditioned medium. MDA-MB-231 cells were cultured in 2%
serum-containing medium in the presence of 20 µM MKC8866 or an equal volume
of vehicle (DMSO). After 48 h, the supernatant was removed, ﬁltered, and the
resultant conditioned medium was used for further experiments. In the case of
neutralizing antibody experiments, a portion of the conditioned medium post
neutralization was analyzed by ELISA to conﬁrm successful neutralization.
Human XL Cytokine Array. We used a Human XL Cytokine Array kit (R&D
systems, ARY022) as per manufacturers’ instructions. In brief, membranes were
blocked with Buffer 6 for 1 h at room temperature and incubated with conditioned
medium overnight at 4 °C with gentle agitation. The following day, membranes
were washed three times for 10 min with wash buffer. Detection antibody cocktail
was added to each membrane for 1 h at room temperature followed by washing.
Streptavidin-HRP (2 ml) was added to each membrane and incubated for 30 min at
room temperature. Membrane washes were repeated and signals were visualized by
addition of Chemi Reagent Mix (2 ml).
ELISA. IL-6 (DY206), IL-8 (DY208), CXCL1 (DY275), GM-CSF (DY215), and
TGFβ2 (DY302) DUOSET ELISA’s were purchased from R&D Systems and carried
out as per manufacturer’s instructions.
RNA extraction, PCR, and Q-PCR. Total RNA was isolated using TRI Reagent
(Sigma-Aldrich, T9424) according to the manufacturer’s instructions. In total,
500–2000 ng of RNA was reverse transcribed using Superscript II (Invitrogen
18064014). For standard PCR, products were visualized using 1% agarose gels. Q-
PCR reactions were performed using Takyon ROX Master Mix (Eurogentec
UFRP5XC0501) and the StepOne Plus platform (Applied Biosystems). Target
transcript levels were normalized to GAPDH, and relative abundance was deter-
mined using the ΔΔCt method. Transcript-speciﬁc TaqMan assays were purchased
from Integrated DNA Technologies. For tumor xenografts, XBP1u and XBP1s
transcript levels were normalized to the average Ct of control gene, ACTB using the
ΔΔCt method. MDA-MB-231 cDNA was used as the control sample for ΔΔCt
calculations. Percentage XBP1 mRNA splicing was determined by calculated as
XBP1s/(XBP1s+ XBP1u) × 100. Sequences of primers and probes used are detailed
in Supplementary Table 3.
Q-PCR to determine relative XBP1 splicing in patient samples. The Galway
University Hospitals Clinical Research Ethics Committee approved the use of
human tissue samples following informed patient consent. Patients provided
written informed consent for use of samples, and work was performed according to
the principles of the Declaration of Helsinki. Breast tissue samples (basal (n= 5),
luminal (n= 4), TAN (n= 4)) were harvested in theater at University Hospital
Galway. Samples were preserved by immediate immersion in RNAlater® (Sigma-
Aldrich R0901) and subsequently stored at −80 °C until required for RNA
extraction. RNA quality was determined by resolving at least 250 ng of total RNA
on a 1% sodium borate agarose gel, and samples displaying degradation were
excluded from the study. An aliquot of 500 ng of total RNA was reverse transcribed
as described above. Total XBP1 and XBP1s transcript levels were normalized to the
average Ct of control genes, PPIA and MRPL19 using the ΔΔCt method. A pool of
cDNA was used as an inter-plate/run control and as the control sample for ΔΔCt
calculations. Results are displayed as: relative XBP1s abundance/relative XBP1 total
abundance.
Transient knockdown and overexpression. For knockdown, MDA-MB-231 cells
were transfected with 25 nM of Dharmacon On-Target SMARTpool Plus siRNA
targeting XBP1 (L-009552-00), IRE1 (L-004951-02), or non-targeting control (NC)
siRNA (D-001810-01-20) using Dharmafect 4 (Dharmacon T-2004-02) according
to the manufacturer’s instructions.
Stable shRNA knockdown. pLKO control vector (SHC001) and human XBP1
(SHCLND-NM_005080) lentiviral shRNA constructs were purchased from Sigma-
Aldrich. Lentivirus was generated by co-transfecting the above plasmids with
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second-generation lentivirus-packaging system (Addgene, pMD2.G cat. no. 12259,
psPAX2 cat. no. 12260, pRSV-Rev cat. no. 12253) using JET PEI transfection
reagent (Polyplus Transfection, cat. no. 101-01N) into HEK 293T cells. Virus-
containing supernatant was harvested and ﬁltered through 0.22 μm ﬁlter (Sarstedt
Filtropur 83.1826.001). Cells were transduced with this media in presence of 5 μg
ml−1 polybrene (Merck Millipore TR-1003-G). XBP1 shRNA cells were selected for
72 h in 2 μg ml−1 of puromycin (Sigma-Aldrich, P8833).
Microarray analysis. MDA-MB 231 cells were seeded at 5 × 105 cells per T25
ﬂask. Cells were treated with vehicle (DMSO) or MKC8866 (20 μM) for 4 and 24
h. RNA was extracted using a combination of phenol-chloroform extraction
(TRI reagent T9424), and Qiagen RNeasy column (74104) extraction methods. A
portion of the RNA was taken for pre-analysis. Inhibition of XBP1 splicing was
conﬁrmed by RT-PCR before the samples were sent to EMBL for analysis. RNA
quality was determined by amplifying 5′ and 3′ ends of the GAPDH transcript
upon OligoDt-primed reverse transcription, and by capillary electrophoresis
upon receipt at EMBL. The experiment was performed in triplicate. MicroArray
analysis was performed on Affymetrix GeneChip Human Transcriptome Array
2.0 in at the EMBL genetics core facility in Heidlberg, Germany. The generated
data have been deposited in the Gene Expression Omnibus (GEO) and are
publicly available under the GEO accession number GSE99766. The data were
analyzed using GeneSpring GX software (Life Sciences Informatics, Agilent)
whereby genes with P value below 0.05 and absolute fold change greater than 1.3
were considered differentially expressed between the two conditions and selected
as potential IRE1 markers for further analysis. Initial candidate markers were
subsequently curated in a training data set by utilizing them to hierarchically
cluster, in a semi-supervised manner, a panel of 27 breast cancer line gene
expression data sets (GEO accession GSE50832)41. Hierarchical clustering uti-
lizing the 401 candidate markers revealed two robust groups of genes that either
negatively or positively correlated with expected IRE1 activity. Genes strongly
associated with either group were further prioritized using BioInfoMiner tool to
generate an 83-gene signature predictive of IRE1 activity (Supplementary
Table. 1). This IRE1 83-gene signature was then utilized for unsupervised
clustering of a cohort of 595 breast cancer tumors from the publicly available
The Cancer Genome Atlas (TCGA) database42. Breast cancer tumor groups with
gene expression proﬁles corresponding with high (n= 63) and low (n= 79)
IRE1 activity (as predicted by the IRE1 gene signature) from both ends of the
spectrum were taken for further analysis and comparison. P values for box plots
were calculated using a two-tailed t test with Welch’s correction and performed
with GraphPad Prism software (GraphPad Software, San Diego, CA, USA).
GSEA between the two groups was performed with GSEA software (Broad
Institute), using transcriptome proﬁling data from the high IRE1 and low IRE1
tumor sets (TCGA) and pre-deﬁned gene signatures from the Molecular Sig-
nature Database (MSigDB). The Pearson correlation coefﬁcient was calculated
between predicted IRE1 activity score and every other gene, across the cohort of
595 patient samples from TCGA, resulting in a list of genes ranked according to
their correlation with IRE1 activity. GSEA with Gene Ontology terms (GO) of
the ranked list was performed with GSEA software (Broad Institute). GS
enrichment scores were normalized using 1000 gene permutations and GO terms
with false discovery rates under 0.25 were considered signiﬁcantly enriched.
Mammosphere formation assay. MDA-MB-231 cells were treated with 10 nM
paclitaxel for 72 h. Cells were washed once with complete growth medium then
allowed to recover in complete medium containing vehicle (DMSO), MKC8866
(20 μM), IL-8 (500 ng ml−1) neutralizing antibody, CXCL1 (10 μg ml−1) neu-
tralizing antibody, recombinant CXCL1 (500 pg ml−1), or recombinant IL-8 (3 ng
ml−1), as indicated for a further 72 h. After recovery cell viability was determined
using trypan blue staining. Viable cells from each treatment were seeded in tri-
plicate at 1 × 103 cells per well in 96 well ultra-low attachment surface plates
(Corning, 10554961) in DMEM/F12 medium supplemented with B27-supplement
(ThermoFisher, 12587010) and 20 ng ml−1 epidermal growth factor. Completely
untreated cells were also seeded as a control. Mammospheres measuring >40 μm
were quantiﬁed in ﬁve ﬁelds per well, and mammosphere formation efﬁciency (%)
was determined using the following formula: (number of mammospheres > 40 μm/
number of cells seeded) × 100.
Immunohistochemistry. The study was conducted with human samples and
clinical data of Rennes Biobank Breast Cancer Collection (BRIF number: BB-
0033-00056) certiﬁed NF S96900 for receipt preparation preservation and pro-
vision of biological resources. All patients provided written informed consent to
the use of surgical specimens and clinic-pathological data for research purposes
(as required by the French Committee for the Protection of Human Subjects
(CCPPRB)). Rennes CCPPRB approved the use of tumor tissues for this study (6
May 2013: no. 357/2013). Collection of tumors was approved by French Minister
of higher education and research (no. AC-2008-141). Samples were embedded in
parafﬁn and cut into 3 µm sections. Ventana OMNIMap (ROCHE) detection kit
procedure was optimized on the Discovery instrument and was preset. Appli-
cations of the Ventana High Temperature Liquid Coverslip (LCS, cat. no.
650010, Ventana) occurred throughout the automated protocol as appropriate.
Likewise, the slides were rinsed between steps with Ventana Tris-based Reaction
buffer. Following deparafﬁnation with Ventana EZ Prep at 75 °C for 8 min,
antigen retrieval was performed using Ventana proprietary, Tris-based buffer
solution CC1 (pH 8). Endogenous peroxidase was blocked with Inhibitor-D 3%
H2O2 for 10 min at room temperature. After rinsing, slides were incubated at 37
°C for 60 min with a 1:1000 dilution of mouse polyclonal XBP143, rabbit poly-
clonal IL-8 (Santa Cruz SC-7922, 1:50), or rabbit polyclonal CXCL1 (R&D
systems MAB4531, 1:50). Tissue sections were incubated for 30 min with con-
jugated secondary antibody and visualized following substrate addition.
Immunohistochemistry staining was quantiﬁed by an independent investigator
using a blinded approach according to the methodology outlined
previously44.
In vivo MDA-MB-231 xenograft model. All animal experiments were performed
in accordance with the ethical guidelines of the IACUC committee at Charles
River Laboratories, Piedmont, South Carolina (Approved study protocol IACUC
ASP #: 980701). Female athymic nude mice (Crl:NU(Ncr)-Foxn1nu, Charles
River) were implanted subcutaneously in the right ﬂank with 5 × 106 MDA-MB-
231 cells (0.1 ml cell suspension in PBS). Mice with tumors measuring between
225 and 250 mm3 were randomized into six treatment groups consisting of ten
mice with individual tumor volumes ranging from 196 to 288 mm3 and group
mean tumor volumes from 225 to 227 mm3 (considered day 1 of treatment).
Change in tumor volume was monitored by calipers two times per week with
tumor volume calculated as V= (L × S2)/2 by measuring the long (L) and short
(S) axes of tumors. Paclitaxel (Lot CP2N10007) was purchased as a dry powder
from Phyton Biotech, LLC (Fort Worth, TX). A 10 mg ml−1 paclitaxel stock
solution in 50% ethanol: 50% Cremophor EL was prepared and stored at room
temperature protected from light prior to dosing. On each day of dosing, an
aliquot of the paclitaxel stock was diluted with 5% dextrose in water (D5W)
to yield a 1.0 mg ml−1 paclitaxel dosing solution in a vehicle consisting of
5% ethanol: 5% Cremophor EL: 90% D5W (Vehicle 1) which provided the
10 mg kg−1 dose in a 10 ml kg−1 dosing volume. Mice were administered
10 mg kg−1 paclitaxel weekly by intravenous injection. The IRE1 inhibitor,
MKC8866, was administered at a dose volume of 10 ml kg−1 from a 30 mg ml−1
suspension in 1% microcrystalline cellulose in a simple sugar at 300 mg kg−1
daily by oral gavage (Vehicle 2). Treatment groups were as follows: For Group 1,
the paclitaxel vehicle was administered intravenously weekly and the MKC8866
vehicle was administered orally daily throughout the course of the study. For
Groups 2–6, paclitaxel was administered weekly throughout the course of
the study. In combination with paclitaxel, MKC8866 was also administered
orally daily from day 1 to 28 (Group 3), from day 14 to 60 (Group 4), from day
28 to 60 (Group 5), and from day 1 to 60 (Group 6). Treatments in all groups
were administered until tumors reached maximal size or day 60, whichever
came ﬁrst.
For the xenograft regrowth post-paclitaxel in vivo experiments, female
athymic nude mice (Crl:NU(Ncr)-Foxn1nu, Charles River) were implanted
subcutaneously in the right ﬂank as described above. Following establishment of
palpable tumors, mice were randomized into treatment groups consisting of 10
mice per group with group mean tumor volumes from 227 to 230 mm3
(considered day 1 of treatment). A 7.5 mg ml−1 paclitaxel stock solution in 50%
ethanol: 50% Cremophor EL was prepared and stored at room temperature
protected from light prior to dosing. On each day of dosing, an aliquot of the
paclitaxel stock was diluted with 5% dextrose in water (D5W) to yield a 0.75
mg ml-1 paclitaxel dosing solution in a vehicle consisting of 5% ethanol: 5%
Cremophor EL: 90% D5W (Vehicle 1) which provided the 7.5 mg kg−1 dose in a
7.5 ml kg−1 dosing volume. Mice were administered 7.5 mg kg−1 paclitaxel once
every other day for ﬁve doses by intravenous injection. MKC8866 was
administered daily for 28 days at a dose volume of 10 ml kg−1 from a 30 mg ml−1
suspension in 1% microcrystalline cellulose in a simple sugar at 300 mg kg−1
daily by oral gavage (Vehicle 2). Group 1 received paclitaxel (7.5 mg kg−1) alone
while Group 2 received paclitaxel (7.5 mg kg−1) plus 300 mg kg−1 MKC8866.
If, during the course of the study, tumors became necrotic or if measurement
of the tumor in two dimensions was not possible using calipers, measurement
was stopped. Mice were observed frequently for health and overt signs of any
adverse treatment-related side effects, and noteworthy clinical observations were
recorded. Individual body weight loss was monitored per protocol, and any
animal whose weight exceeded the limits for acceptable body weight loss was
euthanized. Acceptable toxicity was deﬁned as a group mean body weight loss of
<20% during the study and not more than one treatment related death among
ten treated animals, or 10%. Any dosing regimen resulting in greater toxicity was
considered above the maximum tolerated dose.
Statistical analysis. Assumptions concerning the data (normal distribution and
similar variation between experimental groups) were examined for appropriateness
before statistical tests were conducted. Statistical analysis was carried out using
pairwise single factor ANOVA, unpaired two-tailed Student’s t test, or two-tailed
t test with Welch’s correction as indicated. Values with P < 0.05 are considered
statistically signiﬁcant.
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Data availability. Microarray data supporting the ﬁndings of this study have been
deposited in the Gene Expression Omnibus and are publicly available under the
GEO accession number GSE99766.
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